“This was not an ‘unfortunate incident’”: PTPA Director slams anti-doping processes following Swiatek suspension

Iga Swiatek announced on Thursday that she tested positive for doping in August and received a one-month ban, reigniting debates over how authorities handle doping cases. The Polish player tested positive for trimetazidine and received support from the WTA, but the Professional Tennis Players Association (PTPA) director, Ahmad Nassar, criticised the overall management of these cases.

Months ago, Jannik Sinner was at the centre of controversy after it emerged he had tested positive for doping twice. Investigations concluded that he bore no fault or negligence, and he was not suspended—a decision many perceived as preferential treatment compared to other players who faced lengthy bans in similar circumstances.

This time, Swiatek tested positive in August and was handed a one-month suspension after it was determined she bore no significant fault or negligence. The WTA swiftly supported the five-time Grand Slam champion, releasing a statement: “The WTA fully supports Iga during this difficult time. Iga has consistently demonstrated a strong commitment to fair play and upholding the principles of clean sport, and this unfortunate incident highlights the challenges athletes face in navigating the use of medications and supplements.

“The WTA remains steadfast in our support for a clean sport and the rigorous processes that protect the integrity of competition. We also emphasize that athletes must take every precaution to verify the safety and compliance of all products they use, as even unintentional exposure to prohibited substances can have significant consequences.”

Ahmad Nassar, the Executive Director of the PTPA, an organisation created by Novak Djokovic in 2019 to defend players' interests, strongly criticised the handling of doping cases: “I’m sorry. This was not an ‘unfortunate incident.’ A real unfortunate incident is something you cannot control. Tennis can – and should! – no, must! – control its own anti-doping process,” he wrote on X (formerly Twitter).

“Athletes indeed face ‘challenges.’ Like, the weather. And their opponents. But the messy, tennis-establishment-imposed anti-doping process is not some ‘challenge’ athletes must overcome. That’s a cop-out,” he added.

“What ‘precaution’ should Iga have taken here? Pre-test melatonin on the minuscule chance it was contaminated? Come on. Perhaps the tours which claim to ‘fully support’ players should offer pre-tested common medications, like melatonin, to all players? What’s that? Sounds unreasonable? Oh ok – then why do we place even more unreasonable standards and burdens on individual athletes???”

Denis Shapovalov quickly weighed in on social media, referencing Swiatek: “1 month ban eh,” he wrote. Months earlier, he had been among the most vocal critics of how Sinner’s case was handled. Later, he even mentioned Simona Halep and Mikael Ymer as examples of what he called “inconsistent rules.”